Home > Cardiology > ACS patients with several metabolic risk factors may benefit most from PCSK9 inhibitors

ACS patients with several metabolic risk factors may benefit most from PCSK9 inhibitors


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The Lancet Diabetes & Endocrinology
Reuters Health - 20/04/2022 - Adults with a history of acute coronary syndrome (ACS) and multiple metabolic risk factors may benefit the most from treatment with the PCSK9 inhibitor alirocumab, according to a post-hoc analysis of the ODYSSEY OUTCOMES trial. "Counting the number of risk factors could be a simple way for clinicians to identify patients considered for PCSK9 inhibitor therapy after acute coronary syndrome," Dr. Petr Ostadal with Na Homolce Hospital, in Prague, Czech Republic, and colleagues suggest in a paper in The Lancet Diabetes & Endocrinology. The authors of a linked comment say this analysis shows that "every additional metabolic risk factor, other than low HDL cholesterol, identifies a population at greater and greater residual cardiovascular risk and for whom reducing LDL cholesterol results in greater absolute risk reduction." "Therefore fewer patients need to be treated to prevent each cardiovascular event, resulting in greater cost...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on